journal
https://read.qxmd.com/read/33084873/assessment-and-comparison-of-performance-of-abcd-10-and-scorten-in-prognostication-of-epidermal-necrolysis
#1
Hui Kai Koh, Stephanie Fook-Chong, Haur Yueh Lee
Importance: Epidermal necrolysis is a rare severe cutaneous drug reaction associated with high mortality. The ABCD-10 score (age, bicarbonate, cancer, dialysis, 10% body surface area), a new prognostic score for mortality in epidermal necrolysis, was recently developed and validated in the US. However, to our knowledge, it remains to be externally validated in other cohorts. Objective: To assess ABCD-10 among patients in a contemporary Asian cohort and compare its performance with the Score of Toxic Epidermal Necrosis (SCORTEN) and study the associations of time and immunomodulatory therapy with the performance of ABCD-10 and SCORTEN...
October 21, 2020: JAMA Dermatology
https://read.qxmd.com/read/33084872/improving-outcomes-for-patients-with-epidermal-necrolysis
#2
Robert G Micheletti, Megan H Noe
No abstract text is available yet for this article.
October 21, 2020: JAMA Dermatology
https://read.qxmd.com/read/33084853/association-of-mohs-micrographic-surgery-vs-wide-local-excision-with-overall-survival-outcomes-for-patients-with-melanoma-of-the-trunk-and-extremities
#3
Addison M Demer, Jamie L Hanson, Ian A Maher, Walter Liszewski
Importance: Although previous database studies suggest that Mohs micrographic surgery (MMS) treatment is associated with improved overall survival (OS) for head and neck melanomas, outcomes for trunk and extremity (T&E) tumors have not been adequately evaluated. Objective: To assess survival outcomes for patients with melanomas of the T&E treated with MMS vs wide local excision (WLE). Design, Setting, and Participants: This retrospective cohort study examined deidentified data from the National Cancer Database between 2004 and 2015...
October 21, 2020: JAMA Dermatology
https://read.qxmd.com/read/33052394/contribution-of-genetics-to-the-susceptibility-to-hidradenitis-suppurativa-in-a-large-cross-sectional-dutch-twin-cohort
#4
Kelsey R van Straalen, Errol P Prens, Gonneke Willemsen, Dorret I Boomsma, H H van der Zee
Importance: Hidradenitis suppurativa is a chronic, inflammatory skin disease in which genetic factors are considered to play a role, with up to 38% of patients reporting a family history. Variations in the γ-secretase genes are found mainly in familial cases with an autosomal dominant pattern of inheritance. These variations are rare in the general population with hidradenitis suppurativa, even in patients who report a family history of the disease. Objective: To assess the heritability of hidradenitis suppurativa in a nationwide Dutch twin cohort...
October 14, 2020: JAMA Dermatology
https://read.qxmd.com/read/33052389/fibroblast-growth-factor-receptor-inhibitors-and-nonuremic-calciphylaxis
#5
Jesse Hirner, James M Cleary, Anthony Sheets, George Murphy, Nicole LeBoeuf
No abstract text is available yet for this article.
October 14, 2020: JAMA Dermatology
https://read.qxmd.com/read/33052383/papuloerythroderma-of-ofuji
#6
Sizhe Li, Xiaoling Yu, Tao Wang
No abstract text is available yet for this article.
October 14, 2020: JAMA Dermatology
https://read.qxmd.com/read/33052382/effect-of-risankizumab-on-patient-reported-outcomes-in-moderate-to-severe-psoriasis-the-ultimma-1-and-ultimma-2-randomized-clinical-trials
#7
Matthias Augustin, Jo Lambert, Carla Zema, Elizabeth H Z Thompson, Min Yang, Eric Q Wu, Viviana Garcia-Horton, Ziqian Geng, Joaquin M Valdes, Avani Joshi, Kenneth B Gordon
Importance: Demonstrating the value of therapies from a patient's perspective is increasingly important for patient-centered care. Objective: To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe psoriasis. Design, Setting, and Participants: The UltIMMa-1 and UltIMMa-2 studies were replicate 52-week phase 3, randomized, multisite, double-blind, placebo-controlled and active comparator-controlled trials conducted in 139 sites (including hospitals, academic medical centers, clinical research units, and private practices) globally in Asia-Pacific, Japan, Europe, and North America...
October 14, 2020: JAMA Dermatology
https://read.qxmd.com/read/33026427/prevalence-of-dermatitis-herpetiformis-within-the-icureceliac-patient-powered-research-network-patient-characteristics-and-dietary-counseling
#8
Bridget E Shields, Joel M Gelfand, Lynne Allen-Taylor, Misha Rosenbach
No abstract text is available yet for this article.
October 7, 2020: JAMA Dermatology
https://read.qxmd.com/read/33026422/achieving-equitable-care-for-people-with-disabilities-considerations-for-the-dermatologist
#9
Janelle S Nassim, Alice J Watson, Jennifer K Tan
No abstract text is available yet for this article.
October 7, 2020: JAMA Dermatology
https://read.qxmd.com/read/33026421/assessment-of-incidence-rate-and-risk-factors-for-keratoacanthoma-among-residents-of-queensland-australia
#10
Magdalena Claeson, Nirmala Pandeya, Jean-Claude Dusingize, Bridie S Thompson, Adele C Green, Rachel E Neale, Catherine M Olsen, David C Whiteman
Importance: Keratoacanthoma (KA) is a common and generally benign keratinocyte skin tumor. Reports of the incidence rates of KA are scant. In addition, the risk factors for KA are not well understood, although associations with UV radiation exposure and older age have been described. Objective: To investigate the incidence rate of KA and the risk factors for developing KA. Design, Setting, and Participants: The study included data from 40 438 of 193 344 randomly selected residents of Queensland, Australia, who participated in the QSkin Sun and Health (QSkin) prospective population-based cohort study...
October 7, 2020: JAMA Dermatology
https://read.qxmd.com/read/33026413/a-solitary-lump-on-the-scalp
#11
Lucas Samuel Perinazzo Pauvels, Beatriz da Silva Souza, Juliano Peruzzo
No abstract text is available yet for this article.
October 7, 2020: JAMA Dermatology
https://read.qxmd.com/read/33001147/association-of-secukinumab-treatment-with-tuberculosis-reactivation-in-patients-with-psoriasis-psoriatic-arthritis-or-ankylosing-spondylitis
#12
Boni E Elewski, John W Baddley, Atul A Deodhar, Marina Magrey, Phoebe A Rich, Enrique R Soriano, Jennifer Soung, Weibin Bao, Dorothy Keininger, Kwaku Marfo, Manmath Patekar, Abhishek Sharma, Abhijit Shete, Mark Gabriel Lebwohl
Importance: Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor inhibitors may be associated with increased risk of TB and LTBI reactivation, although data are limited on the risks of TB with use of newer biologics. Objective: To assess the association of secukinumab with reporting of active TB development, TB reactivation, and LTBI activation as an adverse event (AE) in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis...
September 30, 2020: JAMA Dermatology
https://read.qxmd.com/read/33001141/ventriculoperitoneal-shunt-infection
#13
Cristina López-Sánchez, Eduardo Rozas-Muñoz, Juan Francisco Mir-Bonafé
No abstract text is available yet for this article.
September 30, 2020: JAMA Dermatology
https://read.qxmd.com/read/33001140/efficacy-and-safety-of-baricitinib-combined-with-topical-corticosteroids-for-treatment-of-moderate-to-severe-atopic-dermatitis-a-randomized-clinical-trial
#14
Kristian Reich, Kenji Kabashima, Ketty Peris, Jonathan I Silverberg, Lawrence F Eichenfield, Thomas Bieber, Aleksandra Kaszuba, Jill Kolodsick, Fan E Yang, Margaret Gamalo, Dennis R Brinker, Amy M DeLozier, Jonathan M Janes, Fabio P Nunes, Jacob P Thyssen, Eric L Simpson
Importance: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies. Objective: To assess the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background topical corticosteroid (TCS) therapy in adults with moderate to severe AD who previously had an inadequate response to TCS therapy. Design, Setting, and Participants: This double-blind, placebo-controlled, phase 3 randomized clinical trial, BREEZE-AD7 (Study of Baricitinib [LY3009104] in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis) was conducted from November 16, 2018, to August 22, 2019, at 68 centers across 10 countries in Asia, Australia, Europe, and South America...
September 30, 2020: JAMA Dermatology
https://read.qxmd.com/read/32997094/tofacitinib-for-the-treatment-of-nail-lesions-and-palmoplantar-pustulosis-in-synovitis-acne-pustulosis-hyperostosis-and-osteitis-syndrome
#15
Chen Li, Zhaohui Li, Yihan Cao, Li Li, Feng Li, Yueting Li, Dingkun Xiong, Xia Wu, Wen Zhang, Xiaofeng Zeng
Importance: Nail involvement is common in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, which has a strong association with quality of life in patients with SAPHO. Tofacitinib is an oral Janus kinase inhibitor that has been previously shown to be effective for nail psoriasis. Objective: To assess the efficacy and safety of tofacitinib for the treatment of nail involvement in SAPHO syndrome. Interventions: Participants received tofacitinib, 5 mg, twice daily, for 12 weeks...
September 30, 2020: JAMA Dermatology
https://read.qxmd.com/read/32997093/error-in-abstract
#16
(no author information available yet)
No abstract text is available yet for this article.
September 30, 2020: JAMA Dermatology
https://read.qxmd.com/read/32965495/safety-and-efficacy-of-vp-102-a-proprietary-drug-device-combination-product-containing-cantharidin-0-7-w-v-in-children-and-adults-with-molluscum-contagiosum-two-phase-3-randomized-clinical-trials
#17
Lawrence F Eichenfield, Wendy McFalda, Bradford Brabec, Elaine Siegfried, Pearl Kwong, Mark McBride, Jayson Rieger, Cynthia Willson, Matthew Davidson, Patrick Burnett
Importance: Molluscum contagiosum (MC) is a common viral skin infection that primarily affects children. Cantharidin, a topical vesicant, has a long history of use for MC in compounded formulations, but the safety and efficacy of doses, regimens, and application methods have not been demonstrated in large-scale trials. Objective: To determine the safety and efficacy of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle in individuals with MC...
September 23, 2020: JAMA Dermatology
https://read.qxmd.com/read/32965485/cellulitis
#18
Jane Han, Adam Faletsky, Arash Mostaghimi
No abstract text is available yet for this article.
September 23, 2020: JAMA Dermatology
https://read.qxmd.com/read/32965477/error-in-byline
#19
(no author information available yet)
No abstract text is available yet for this article.
September 23, 2020: JAMA Dermatology
https://read.qxmd.com/read/32965475/characterizing-disease-features-and-other-medical-diagnoses-in-patients-with-pityriasis-rubra-pilaris
#20
Katherine Halper, Benjamin Wright, Nolan J Maloney, Mindy M Kim, Vignesh Ravi, Scott Worswick, Donald K Lei
No abstract text is available yet for this article.
September 23, 2020: JAMA Dermatology
journal
journal
44126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"